explore -WSS

explore

author：focus 2025-09-29 12:29:57 - browse：379

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Yancopoulos of Regeneron works to expand Dupixent success

hotspot

WSS

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Report: NIH

What will save rural psychiatry services? Higher Medicaid payments

Erich Jarvis studies song birds to learn about human stuttering

hotspot

explore

Wikipedia

Virginia high school admissions case could be legal follow

Cancer, immunology, HIV research ensnared in fetal tissue politics

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

What does generative AI mean for health care? We asked experts

Biohaven protein

Drug repurposing or repositioning? The language matters

Mirador, a new biotech startup, launches with $400 million

Anesthesiologist group: stop taking Ozempic before surgery

Mirador, a new biotech startup, launches with $400 million

entertainment

This gene therapy has record $4.25 million price. It's saved children.

Biotech investment managers search for lucrative opportunities

Addiction doctors spar with methadone clinics over legislation

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

AI used to predict Covid

Texas board proposes rules on abortion law emergency exemption

focus

hotspot

knowledge

focus